Buscar

Barra de búsqueda
01/08/2025 Empasiprubart in Multifocal Motor Neuropathy: Safety and Efficacy Data From the Phase 2 ARDA Study
Querol, L, Harbo, T, Peric, S, Hussain, Y, Cadour, S, Van de Walle, I, Persson, E, Vujcic, M, Van de Steen, O, Allen, J, Nobile-Orazio, E, Attarian, S, Karam, C, Katzberg, H, Stettner, M, Rinaldi, S, van der Pol, WL. Empasiprubart in Multifocal Motor Neuropathy: Safety and Efficacy Data From the Phase 2 ARDA Study. JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM. 2025; 30(3)DOI:. PMID:. IF:3.200(Q2/4D).
01/08/2025 Baseline Characteristics of the First 100 Study Participants with Multifocal Motor Neuropathy in the iMMersioN study
Hewamadduma, C, Peric, S, Claeys, K, Querol, L, Altamimi, S, Van de Walle, I, Persson, E, Van Hoomissen, I, Szmyd, G, Vujcic, M, Cadour, S, Van de Steen, O, Arvin-Berod, C, Allen, J. Baseline Characteristics of the First 100 Study Participants with Multifocal Motor Neuropathy in the iMMersioN study. JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM. 2025; 30(3)DOI:. PMID:. IF:3.200(Q2/4D).
01/08/2025 Riliprubart Phase 3 MOBILIZE and VITALIZE Trials for CIDP are Actively Enrolling Globally
Falzone, Y, Sommer, C, Querol, L, Allen, J, Merkies, I, Van Doorn, P, Wallstroem, E, Lu, Y, Alonso-Alonso, M, Atassi, N, Lewis, RA. Riliprubart Phase 3 MOBILIZE and VITALIZE Trials for CIDP are Actively Enrolling Globally. JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM. 2025; 30(3)DOI:. PMID:. IF:3.200(Q2/4D).
01/08/2025 Efgartigimod in Pretreated CIDP With Persistent Disease Activity or Progressive/Relapsing Active Disease: ADHERE Analysis
Stettner, M, Allen, J, Rinaldi, S, Pinter, GL, Querol, L, Magy, L, De Roeck, A, Van Hoorick, B, Hofman, E, Istas, G, Skripuletz, T, Lewis, R, Van Doorn, PA. Efgartigimod in Pretreated CIDP With Persistent Disease Activity or Progressive/Relapsing Active Disease: ADHERE Analysis. JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM. 2025; 30(3)DOI:. PMID:. IF:3.200(Q2/4D).
01/08/2025 Comparative Effectiveness In IGOS: ANX005 Versus Intravenous Immunoglobulin or Plasma Exchange For Guillain-Barre Syndrome
Wiegers, E, Steyerberg, E, Rajpar, A, Paliwal, P, Kanani, K, Kroon, HA, Dananberg, J, Cornblath, D, Willison, H, Kim, M, Gorson, K, Querol, L, Hartung, HP, Islam, Z, van Doorn, PA, Jacobs, B. Comparative Effectiveness In IGOS: ANX005 Versus Intravenous Immunoglobulin or Plasma Exchange For Guillain-Barre Syndrome. JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM. 2025; 30(3)DOI:. PMID:. IF:3.200(Q2/4D).
01/08/2025 Development and Validation of a Digital Tool to Simplify Use of Guidelines For CIDP Diagnosis
Dymm, B, Van den Bergh, P, London, Z, Lewis, R, Querol, L, Harbo, T, Allen, J, Hadden, R, Van Doorn, PA. Development and Validation of a Digital Tool to Simplify Use of Guidelines For CIDP Diagnosis. JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM. 2025; 30(3)DOI:. PMID:. IF:3.200(Q2/4D).
01/08/2025 Serum Neurofilament Light Chain in The International GBS Outcome Study: Predicting Disease Course and Outcome
Rajpar, A, Wiegers, E, Thomma, R, van Tilburg, S, Plomp, L, Sammelius, L, van Rijs, W, Harbo, T, Hartung, HP, Islam, Z, Lunn, M, Querol, L, Huizinga, R, Jacobs, B. Serum Neurofilament Light Chain in The International GBS Outcome Study: Predicting Disease Course and Outcome. JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM. 2025; 30(3)DOI:. PMID:. IF:3.200(Q2/4D).
01/08/2025 Empasiprubart Versus Intravenous Immunoglobulin in Multifocal Motor Neuropathy Phase 3 Study Design: EMPASSION
Querol, L, Peric, S, Cadour, S, Rigby, S, Van de Walle, I, Persson, E, Vujcic, M, Van de Steen, O, Mashchenko, O, Van Hoomissen, I, Allen, J, Katzberg, H, Kuwabara, S, Stettner, M, Rinaldi, S, van der Pol, WL. Empasiprubart Versus Intravenous Immunoglobulin in Multifocal Motor Neuropathy Phase 3 Study Design: EMPASSION. JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM. 2025; 30(3)DOI:. PMID:. IF:3.200(Q2/4D).